Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
Delayed Nasdaq  -  04:00 2022-11-30 pm EST
62.08 USD   +2.36%
11/29Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
GL
11/29Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
GL
11/29Lantheus Holdings, Inc. Appoints Amanda Morgan as Senior Vice President, Commercial
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

GE Healthcare and Lantheus Holdings Inc Announces Phase III Clinical Trial Finds [╣8F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

09/13/2022 | 08:05am EST

GE Healthcare and Lantheus Holdings Inc. announced that they have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F] flurpiridaz, has met its co-primary endpoints of exceeding a 60% threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD). The findings, shared at the American Society of Nuclear Cardiology (ASNC) Congress, in Florida, U.S., also demonstrate [18F] flurpiridaz Positron Emission Tomography (PET) has higher diagnostic efficacy and image quality in patients with suspected CAD, compared with Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI), the predominant procedure used in nuclear cardiology today. SPECT MPI represents approximately 6 million procedures per year in the U.S. The Phase III Open-Label Study, which involved over 600 patients across sites in the U.S., Europe and Canada assessed the diagnostic efficacy of [18F] flurpiridaz in detecting CAD, the most common form of heart disease and the leading cause of death globally, with invasive coronary angiography as a standard of truth.

More than 120 million people are affected by CAD globally each year and in the U.S. alone, approximately 20 million adults have CAD, with nearly 383,000 deaths recorded in 2020. If approved, this investigational agent would offer the advantages of 18F, with broad available distribution and a half-life of almost two hours, removing the need for it to be manufactured in the immediate vicinity of the imaging department. This longer half-life could also make Flurpiridaz (18F) Injection suitable for exercise stress testing, which is not feasible with existing cardiac PET radiotracers.

GE Healthcare has led the funding and development of [18F] flurpiridaz, and, if the imaging agent is approved, will have global commercialization rights. Lantheus has collaborated on the development and will also collaborate on potential commercialization through a joint steering committee. Lantheus is entitled to royalties based on commercial sales.


ę S&P Capital IQ 2022
All news about LANTHEUS HOLDINGS, INC.
11/29Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
GL
11/29Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
GL
11/29Lantheus Holdings, Inc. Appoints Amanda Morgan as Senior Vice President, Commercial
CI
11/28Lantheus Holdings Secures Chinese Approval for Ultrasound Enhancing Agent
MT
11/28Lantheus Announces the Approval of DEFINITY« (Perflutren Lipid Microsphere) by China's ..
GL
11/28Lantheus Announces the Approval of DEFINITY« (Perflutren Lipid Microsphere) by China's ..
AQ
11/28Lantheus Announces the Approval of DEFINITY« (Perflutren Lipid Microsphere) by China..
CI
11/14POINT Biopharma Global Posts Wider Q3 Loss, Signs License Agreements With Lantheus; Sha..
MT
11/14Lantheus Holdings, Inc. : Entry into a Material Definitive Agreement, Other Events, Financ..
AQ
11/14Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agr..
GL
More news
Analyst Recommendations on LANTHEUS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 917 M - -
Net income 2022 200 M - -
Net Debt 2022 - - -
P/E ratio 2022 21,5x
Yield 2022 -
Capitalization 4 273 M 4 273 M -
Capi. / Sales 2022 4,66x
Capi. / Sales 2023 4,13x
Nbr of Employees 612
Free-Float 97,6%
Chart LANTHEUS HOLDINGS, INC.
Duration : Period :
Lantheus Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LANTHEUS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 60,65 $
Average target price 101,67 $
Spread / Average Target 67,6%
EPS Revisions
Managers and Directors
Mary Anne Heino Chief Commercial Officer
Robert J. Marshall Chief Financial Officer & Treasurer
Brian A. Markison Director
Simon Robinson Senior VP-Research & Pharmaceutical Development
Bela S. Denes Vice President-Medical Affairs
Sector and Competitors